Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With and Without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2838232 (Primary) ; Ritonavir
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 26 Jun 2015 Status changed from suspended to discontinued, according to ClinicalTrials.gov record.
- 05 Jun 2015 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
- 29 May 2015 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov